Immunological and Biochemical Characterization of Coxsackie Virus A16 Viral Particles

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Chong, Pele ^a,b   Guo, Meng Shin ^a   Lin, Fion Hsiao Yu ^a   Hsiao, Kuang Nan ^a   Weng, Shu Yang ^a   Chou, Ai Hsiang ^a   Wang, Jen Ren ^c   Hsieh, Shih Yang ^a   Su, Ih Jen ^a   Liu, Chia Chyi ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CVA16 VACCINE; NEUTRALIZING ANTIBODY; PROTEIN VP1; PROTEIN VP2; PROTEIN VP3; PROTEIN VP4; UNCLASSIFIED DRUG; VIRUS RNA; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; BIOREACTOR; BIOREACTOR DESIGN; COXSACKIE VIRUS A; COXSACKIE VIRUS A16; DRUG PURIFICATION; DRUG SYNTHESIS; FEMALE; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; RABBIT; SUCROSE GRADIENT; TISSUE CULTURE; VIRUS CONCENTRATION; VIRUS INACTIVATION; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS PARTICLE; VIRUS TYPING;

ANIMALS; ANTIBODIES, VIRAL; BIOREACTORS; CAPSID PROTEINS; CENTRIFUGATION, DENSITY GRADIENT; CERCOPITHECUS AETHIOPS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENTEROVIRUS A, HUMAN; EPITOPES; HAND, FOOT AND MOUTH DISEASE; HUMANS; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; NEUTRALIZATION TESTS; RABBITS; VERO CELLS; VIRION;

COXSACKIEVIRUS; HUMAN ENTEROVIRUS 71; MIRIDAE; ORYCTOLAGUS CUNICULUS;

EID: 84870600954     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049973     Document Type: Article

References (45)

1. McMinn PC, (2002) An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26: 91-107.
2. Schmidt NJ, Lennette EH, Ho HH, (1974) An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 129: 304-9.
3. Ho M, Chen ER, Hsu KH, Wu SJT, Chen KT, et al. (1999) The Taiwan Enterovirus Epidemic Working Group. An epidemic of enterovirus 71 infection in Taiwan. N Engl J Med 341: 929-935.
4. Huang SW, Hsu YW, Smith DJ, Kiang D, Tsai HP, et al. (2009) Reemergence of enterovirus 71 in 2008 in Taiwan: Dynamics of genetic and antigenic evolution from 1998 to 2008. J Clin Mincrobiol 47: 3653-3662.
5. Lin KH, Hwang KP, Ke GM, Wang CF, Ke LY, et al. (2006) Evolution of EV71 genogroup in Taiwan from 1998 to 2005: an emerging of subgenogroup C4 of EV71. J Med Virol 78: 254-262.
6. McMinn PC, (2003) Enterovirus 71 in the Asia-Pacific region: An emerging cause of acute neurological disease in young children. Neurological journal of Southeast Asia 8: 57-63.
7. Qiu J, (2008) Enterovirus 71 infection: a new threat to global public health? Lancet Neurol 7: 868-869.
8. Xu J, Qian Y, Wang S, Serrano JMG, Li W, et al. (2010) EV71: An emerging infectious disease vaccine target in the Far East? Vaccine doi:10.1016/j.vaccine.2010.03.003.
9. Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, et al. (2009) Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nature Med 15: 794-797.
10. Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, et al. (2009) Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nature Med 15: 798-801.
11. Lee MS, Chang LY, (2010) Development of enterovirus 71 vaccines. Expert Rev Vaccines 9: 149-156.
12. Arita M, Nagata N, Iwata N, Ami Y, Suzaki Y, et al. (2007) An attenuated strain of enterovirus 71 belonging to genotype A showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol 81: 9386-95.
13. Lin YC, Wu CN, Shih SR, Ho MS, (2002) Characterization of a Vero cell-adapted virulent strain of enterovirus 71 suitable for use as a vaccine candidate. Vaccine 20: 2485-93.
14. Ong KC, Devi S, Cardosa MJ, Wong KT, (2010) Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyetitis against disease. J Virol 84: 661-665.
15. Wu SC, Liu CC, Lian WC, (2004) Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development. Vaccine 22: 3858-64.
16. Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, et al. (2008) Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26: 1855-62.
17. Chiu CH, Chu C, He CC, Lin TY, (2006) Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microbes Infect 8: 1671-8.
18. Wu CN, Lin YC, Fann C, Liao NS, Shih SR, et al. (2002) Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20: 895-904.
19. Tung WS, Bakar SA, Sekawi Z, Rosli R, (2007) DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther 5: 6.
20. Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL, (2007) Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res 125: 61-8.
21. Guang DM, Foo W, Alonso S, Chow VTK, Poh CL, (2007) Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microes Infect 9: 1299-1306.
22. Sivasamugham LA, Cardosa MJ, Tan WS, Yusoff K, (2006) Recombinant Newcastle Disease virus capsids displaying enterovirus 71 VP1 fragment induce a strong immune response in rabbits. J Med Virol 78: 1096-104.
23. Chou AH, Liu CC, Chang CP, Guo MS, Hsieh SY, et al. (2012) Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidate. PLoS ONE 7 (4) (): e34834.
24. Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, et al. (2012) Safety and immunogenicity of a novel human enterovirus 71 vaccine: a randomized, placebo-controlled, double-blind, phase 1 clinical trial. Vaccine doi:10.1016/j.vaccine.2012.03.010.
25. Mao Q, Li N, Yu X, Yao X, Li F, et al. (2011) Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71. Arch Virol DOI 10.1007/s00705-011-1136-3.
26. Liu CC, Lian WC, Butler M, Wu SC, (2007) High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. Vaccine 25: 19-24.
27. Liu CC, Guo MS, Lin FHY, Hsiao KN, Chang KHW, et al. (2011) Purification and characterization of enterovirus 71 viral particls produced from Vero cells grown in a serum-free microcarrier bioreactor system. PLoS ONE 6 (5) (): e20005.
28. Reed LJ, Muench H, (1938) A simple method of estimating 50 percent end-points. Am J Hyg 27: 493-497.
29. Panezutti H, James O, Hansen EJ, Choi Y, Harkness RE, et al. (1993) Identification of surface-exposed B-cell epitopes recognized by H. Influenzae type b P1-specific monoclonal antibody. Infect Immun 61: 1867-1872.
30. Chang JY, Chang CP, Tsai hh, Lee CD, Lian WC, et al. (2012) Selection and characterization of vaccine strain for Enterovirus 71 vaccine devlopment. Vaccine 30: 703-711.
31. Curry S, Fry E, Blakemore W, Abu-Ghazaleh R, Jackson T, et al. (1997) Dissecting the roles of VP0 cleavage and RNA packaging in picornavirus capsid stabilization: the structure of empty capsids of foot-and-mouth disease virus. J Virol 71: 9743-52.
32. Ferguson M, Minor PD, (1990) Differences in conformation of type 3 poliovirus antigenic sites on non-infectious empty particles and infectious virus. J Gen Virol 71: 1271-4.
33. Hummeler K, (1962) Identification of poliovirus particles of different antigenicity by specific agglutination as seen in the electron microscope. Virology 16: 84-90.
34. Minor PD, Schild GC, Wood JM, Dandawate CN, (1980) The preparation of specific immune sera against type 3 poliovirus D-antigen and C-antigen and the demonstration of two C-antigenic components in vaccine strain populations. J Gen Virol 51: 147-56.
35. Plevka P, Perera R, Cardosa J, Kuhn RJ, Rossmann MG. (2012) Crystal structure of human enterovirus 71. Scinecexpress www.sciencemag.org/cgi/content/full/science.1218713/DC1 Accessed 2012 March 1.
36. Wang X, Peng W, Ren J, Hu Z, Xu J, et al. (2012) A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nature Structure & Mol Biol doi:10.1038/nsmb.2255.
37. Blom N, Hansen J, Blaas D, Brunak S, (1996) Cleavage site analysis in picornaviral polyproteins: discovering cellular targets by neural networks. Protein Science 5: 2203-2216.
38. Minor PD, Ferguson M, Katrak K, Wood D, John A, et al. (1991) Antigenic structure of chimeras of type 1 and type 3 polioviruses involving antigenic sites 2, 3 and 4. J Gen Virol 72: 2475-81.
39. Liu CC, Chou Ah, Lien SP, Lin HY, Liu SJ, et al. (2011) Identification and characterization of a cross-neutralization epitope of EV71. Vaccine 29: 4362-73.
40. Chang HW, Liu CC, Lin MH, Ho HM, Yang YT, et al. (2011) Generation of murine monoclonal antibodies which cross-neutralize human enterovirus 71 genotype B isolates. J Virol Methods 173: 189-95.
41. Chang GH, Luo YJ, Wu XY, Si BY, Lin L, et al. (2010) Monoclonal antibody induced with inactived EV71-Hn2 virus protects mice against lethal EV71-Hn2 virus infection. Virol J 7: 106.
42. Brown BA, Pallansch MA, (1995) Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res 39: 195-205.
43. Tan EL, Chow VT, Quak SH, Yeo WC, Poh CL, (2008) Development of multplex real-time hybridization probe reverse transcriptase polymerase chain reaction for specific detection and differentiation of EV71 and coxsackievirus A16. Diagn. Microbiol Infect Dis 61: 294-301.
44. Wu TC, Wang YF, Lee YP, Wang JR, Liu CC, et al. (2007) Immunity to avirulent enterovirus 71 and coxsackie A16 virus potects against enterovirus 71 infection in mice. J Virol 81: 10310-15.
45. Lin Y, Wen K, Pan Y, Wang Y, Che X, et al. (2011) Cross-reactivity of anti-EV71 IgM and neutralizing antibody in series aera of patients infected with enterovirus 71 and coxsackievirus A16. J Immunoassay Immunochemistry 32: 233-43.